Conclusion: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD. Whether rasagiline is associated with ...

Tobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...

Am J Health Syst Pharm. 2006;63(10):915-928. Results of this study suggest that adjunctive rasagiline significantly reduces off time with efficacy similar to that observed by adding entacapone to ...

is a new reversible selective monoamine oxidase B (MAO-B) inhibitor being studied for its potential in treating neurodegenerative diseases like Alzh The ongoing obesity Phase 2 trial is a ...

This production improves thrombin generation and clot formation in patients with hemophilia A or B with inhibitors. The approval is supported by data from the multicenter, open-label phase 3 ...

If you’ve been diagnosed with clinical depression, also known as major depressive disorder (MDD), rest assured there are many treatment options available. Some people will experience only one ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older. The FDA recently approved ...

Rejection sensitive dysphoria is self-perceived shame and distress from rejections at work, school, online, or elsewhere.

MDMA is a mild inhibitor of monoamine oxidase (MAO) and also has direct action on several types of receptors including the 5-HT2 receptor, the M1 muscarinic receptor, the α2-adrenergic receptor, and ...